Biofrontera Inc. disclosed the results of a Phase 2b, randomized, double‑blind study evaluating its Ameluz® photodynamic therapy (PDT) for moderate to severe acne vulgaris. The 34‑patient trial used a single 3‑hour incubation protocol with the BF‑RhodoLED® lamp. Ameluz® produced a 57.97 % reduction in inflammatory lesions compared with 36.51 % in the vehicle group. Twenty‑five percent of Ameluz® patients achieved the co‑primary endpoint of a ≥2‑grade improvement on the 5‑point modified Investigator Global Assessment scale, versus 21.4 % in the vehicle arm. Patient satisfaction was high, with 85.7 % willing to repeat the treatment and 71.4 % rating their aesthetic outcome as “good” or “very good.” Safety was consistent with prior Ameluz® studies; treatment‑related adverse events were mild to moderate, with burning sensation and pruritus reported in both groups and average pain scores during the 3‑hour incubation of 3.4–3.8 for Ameluz® versus 2.0–2.1 for vehicle.
The data support Ameluz®’s potential to expand beyond its current indications for actinic keratosis and superficial basal cell carcinoma. Biofrontera plans to present the Phase 2b results to the U.S. Food and Drug Administration in the third quarter of 2026, a key step toward a new label that could open a substantial revenue stream in the moderate‑to‑severe acne market, which is driven by high spending on oral antibiotics and isotretinoin.
Biofrontera’s strategy to diversify its dermatology portfolio is reinforced by the positive efficacy and patient‑reported outcomes. The company’s Q1 2025 revenue of $8.6 million, a 9 % year‑over‑year increase, was supported by Ameluz® sales and the launch of the RhodoLED XL lamp. The acne data add a new therapeutic avenue that addresses antibiotic resistance and the adverse event profile of current systemic treatments, positioning Ameluz® as a potentially safer, localized alternative.
Investors reacted favorably to the announcement, citing the robust efficacy, high patient satisfaction, and the planned FDA presentation as key drivers of optimism. The results also underscore Biofrontera’s ability to generate meaningful clinical data in a relatively small, well‑controlled study, bolstering confidence in the company’s development pipeline.
The moderate‑to‑severe acne market is sizable, with millions of patients annually and significant spending on existing therapies. Ameluz® could capture a share of this market by offering a treatment that mitigates the risks of antibiotic resistance and systemic side effects, potentially reshaping the therapeutic landscape for acne.
Alongside the acne program, Biofrontera continues to pursue Phase 3 studies for Ameluz® in actinic keratosis on extremities, neck, and trunk, and has received FDA filing acceptance for superficial basal cell carcinoma. The company’s ongoing clinical efforts, coupled with the new acne data, signal a concerted push to broaden Ameluz®’s indications and strengthen its position in dermatology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.